Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHP2306R1 + DHP2306R2
- Development stage
- Unknown
- Lead developer
- Daehwa Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DHP2306R1 + DHP2306R2 is an investigational **oral combination therapy** of two small-molecule drugs under development by DAE HWA PHARM. As of September 2025, the combination has completed phase 1 clinical trials to evaluate its safety and pharmacokinetic drug–drug interactions in healthy adults. Both DHP2306R1 and DHP2306R2 have also been studied as single agents in the same trial. The primary indication in trials is **musculoskeletal pain**. The exact molecular targets and mechanisms of action for each component have not been disclosed in public sources. The drugs are administered orally in a crossover regimen in the clinical setting[1][5].
Beyond the preview
Go deeper on DHP2306R1 + DHP2306R2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHP2306R1 + DHP2306R2.